ofloxacin has been researched along with Bacillus anthracis Infection in 13 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levofloxacin was recently (May 2008) approved by the U." | 6.75 | Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. ( Chien, S; Li, F; Nandy, P; Noel, GJ; Tornoe, CW, 2010) |
| "Ciprofloxacin was administered at 16 mg/kg twice a day." | 5.33 | Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. ( Barnewall, R; Bush, K; Chien, S; Drusano, GL; Estep, J; Hemeryck, A; Kao, LM; Kelley, MF; Minton, N; Olson, PH; Thalacker, FW, 2006) |
| " The objective of this study was to identify a levofloxacin treatment regimen that will serve as an effective therapy for Bacillus anthracis infections and postexposure prophylaxis." | 3.73 | Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. ( Basset, J; Bush, K; Byrne, WR; Deziel, MR; Drusano, GL; Heine, H; Kao, M; Kelly, M; Louie, A; Miller, L, 2005) |
| "Levofloxacin was recently (May 2008) approved by the U." | 2.75 | Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. ( Chien, S; Li, F; Nandy, P; Noel, GJ; Tornoe, CW, 2010) |
| "To date, anthrax is treatable if antibiotics are administered promptly and continued for 60 days." | 2.53 | Alternative pre-approved and novel therapies for the treatment of anthrax. ( Head, BM; Meyers, AF; Rubinstein, E, 2016) |
| "Levofloxacin was administered daily beginning at 6 to 12 h postexposure for 7 treatments." | 1.38 | Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax. ( Bourdage, JS; Duchars, M; Fuerst, TR; Fusco, PC; Leffel, EK; Williamson, ED, 2012) |
| "Ciprofloxacin was administered at 16 mg/kg twice a day." | 1.33 | Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. ( Barnewall, R; Bush, K; Chien, S; Drusano, GL; Estep, J; Hemeryck, A; Kao, LM; Kelley, MF; Minton, N; Olson, PH; Thalacker, FW, 2006) |
| "Levofloxacin was bactericidal at 1 x MIC after 24 h and at 4 x MIC after 12 h, and gatifloxacin was bactericidal at 2 x MIC after 24 h and at 8 x MIC after 12 h." | 1.31 | Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates. ( De Vecchi, E; Drago, L; Gismondo, MR; Lombardi, A; Nicola, L; Valli, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Head, BM | 1 |
| Rubinstein, E | 1 |
| Meyers, AF | 1 |
| Li, F | 1 |
| Nandy, P | 1 |
| Chien, S | 2 |
| Noel, GJ | 1 |
| Tornoe, CW | 1 |
| Yee, SB | 1 |
| Hatkin, JM | 1 |
| Dyer, DN | 1 |
| Orr, SA | 1 |
| Pitt, ML | 2 |
| Weiss, S | 1 |
| Kobiler, D | 1 |
| Levy, H | 1 |
| Pass, A | 1 |
| Ophir, Y | 1 |
| Rothschild, N | 1 |
| Tal, A | 1 |
| Schlomovitz, J | 1 |
| Altboum, Z | 1 |
| Leffel, EK | 1 |
| Bourdage, JS | 1 |
| Williamson, ED | 1 |
| Duchars, M | 1 |
| Fuerst, TR | 1 |
| Fusco, PC | 1 |
| Corey, A | 1 |
| Migone, TS | 1 |
| Bolmer, S | 1 |
| Fiscella, M | 1 |
| Ward, C | 1 |
| Chen, C | 1 |
| Meister, G | 1 |
| Drago, L | 1 |
| De Vecchi, E | 1 |
| Lombardi, A | 1 |
| Nicola, L | 1 |
| Valli, M | 1 |
| Gismondo, MR | 1 |
| Jones, JW | 1 |
| Kiefe, CI | 1 |
| Bossi, P | 1 |
| Bricaire, F | 1 |
| Esel, D | 1 |
| Doganay, M | 1 |
| Sumerkan, B | 1 |
| Deziel, MR | 1 |
| Heine, H | 1 |
| Louie, A | 1 |
| Kao, M | 1 |
| Byrne, WR | 2 |
| Basset, J | 1 |
| Miller, L | 2 |
| Bush, K | 2 |
| Kelly, M | 1 |
| Drusano, GL | 2 |
| Kao, LM | 1 |
| Barnewall, R | 1 |
| Estep, J | 1 |
| Thalacker, FW | 1 |
| Olson, PH | 1 |
| Minton, N | 1 |
| Hemeryck, A | 1 |
| Kelley, MF | 1 |
| Heine, HS | 1 |
| Bassett, J | 1 |
| Hartings, JM | 1 |
| Ivins, BE | 1 |
| Fritz, D | 1 |
| Norris, SL | 1 |
2 reviews available for ofloxacin and Bacillus anthracis Infection
| Article | Year |
|---|---|
Alternative pre-approved and novel therapies for the treatment of anthrax.
Topics: Alpha-Globulins; Anthrax; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal | 2016 |
[Anthrax in the era of biowarfare].
Topics: Adult; Amoxicillin; Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Biological Warfare; Biote | 2003 |
1 trial available for ofloxacin and Bacillus anthracis Infection
| Article | Year |
|---|---|
Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.
Topics: Adolescent; Aging; Anthrax; Anti-Bacterial Agents; Area Under Curve; Biological Availability; Body W | 2010 |
10 other studies available for ofloxacin and Bacillus anthracis Infection
| Article | Year |
|---|---|
Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment.
Topics: Aerosols; Animals; Anthrax; Anti-Bacterial Agents; Antigens, Bacterial; Bacillus anthracis; Bacterem | 2010 |
Antibiotics cure anthrax in animal models.
Topics: Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Antigens, Bacterial; Bacillus anthracis; | 2011 |
Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.
Topics: Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antigens, Bacteri | 2012 |
Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.
Topics: Adjuvants, Immunologic; Administration, Inhalation; Animals; Anthrax; Anthrax Vaccines; Anti-Bacteri | 2013 |
Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; Fluoroquinolones; Gatiflo | 2002 |
Anthrax attacks and practice patterns: a learning opportunity for health care systems.
Topics: Acute Disease; Alabama; Ambulatory Care Facilities; Anthrax; Antibiotic Prophylaxis; Bioterrorism; C | 2002 |
Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Doxycycline; Drug Resistance, Bac | 2003 |
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
Topics: Animals; Anthrax; Anti-Infective Agents; Bacillus anthracis; Humans; Levofloxacin; Macaca mulatta; M | 2005 |
Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.
Topics: Aerosols; Animals; Anthrax; Anti-Bacterial Agents; Area Under Curve; Bacillus anthracis; Computer Si | 2006 |
Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.
Topics: Administration, Inhalation; Aerosols; Animals; Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxi | 2007 |